Youcef Sennour, MD
Geriatric Medicine · Lebanon, NHNPI 1053369280
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,339 of the $1,562 with a category attached, or 85.7%. It is spread thinly across 21 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $865 and has fallen 59.9% since, to $346 in 2025.
Across 77 payments — averaging $20.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$211
- Amarin Pharma, Inc.$179
- Novo Nordisk$159
- Amgen$156
- Johnson & Johnson$147
- AstraZeneca$141
- plus $569 from 15 others
What the payments were for
- Food & beverage$1,33986%
- Education$22314%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 2 | $211 |
| Amarin Pharma, Inc. | 4 | $179 |
| Novo Nordisk | 11 | $159 |
| Amgen | 11 | $156 |
| Johnson & Johnson | 2 | $147 |
| AstraZeneca | 11 | $141 |
| Pfizer | 8 | $123 |
| AbbVie | 5 | $90 |
| Astellas Pharma US Inc | 4 | $63 |
| Merck | 5 | $63 |
| Novartis | 3 | $39 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $32 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $21 |
| Insmed, Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| GSK | 1 | $16 |
| Medtronic | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Boehringer Ingelheim | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few geriatric medicine providers in New Hampshireto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 184 | $210,555 |
| OzempicSemaglutide | 92 | $128,115 |
| JanuviaSitagliptin Phosphate | 66 | $66,648 |
| XareltoRivaroxaban | 50 | $47,210 |
| JardianceEmpagliflozin | 24 | $38,330 |
| TrulicityDulaglutide | 18 | $29,696 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $19,752 |
| MounjaroTirzepatide | 19 | $18,793 |
| MyrbetriqMirabegron | 21 | $18,124 |
| LinzessLinaclotide | 13 | $17,256 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $11,861 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $6,652 |
| Levothyroxine Sodium | 500 | $5,910 |
| Atorvastatin Calcium | 685 | $5,715 |
| Rosuvastatin Calcium | 478 | $5,562 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $123 | $210,555184 claims |
| Novo NordiskOzempic | $159 | $128,11592 claims |
| MerckJanuvia | $63 | $66,64866 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $21 | $48,48937 claims |
| Johnson & JohnsonXarelto | $147 | $47,21050 claims |
| Boehringer IngelheimJardiance | $13 | $38,33024 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $16 | $31,61244 claims |
| AbbVieLinzess, Synthroid | $90 | $20,88567 claims |
| Astellas Pharma US IncMyrbetriq | $63 | $18,12421 claims |
| AstraZenecaSymbicort | $141 | $6,65223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few geriatric medicine providers in New Hampshireon file to place this against a meaningful peer group, so we don't.
Other geriatric medicine in Lebanon
- Suseela KumarLebanon$118
- Stuart LewisLebanon$20
- Kenneth DolkartLebanon$0
- Serena ChaoLebanon$0
- Zohreen BherianiLebanon$0
- Elizabeth MannLebanon$0
- Kayleigh SullivanLebanon$0
- Keron NavarengomManchester$880
- Ana Castellanos MendezConcord$776
- Sourya MahapatraNashua$222
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.